Financings In Brief: ImmunoGen's Oncolysin
Executive Summary
ImmunoGen's Oncolysin: Company notes debenture funds will "buy us more time" to figure out how to achieve the needed number of patients for its Phase III trial of Oncolysin (Mab CD19 anti-B4-blocked ricin) for treatment of B-cell lymphomas and leukemias after autologous bone marrow transplantation. ImmunoGen says it is working on options to shorten the time to completion of the pivotal trial but will need "additional funds before these studies are completed." ImmunoGen may seek a corporate partner or some other relationship, the company says. Nearly 300 patients of an original estimate of 388 have been enrolled in the study so far, the company says; however, the accrual probably will have to be higher, the firm indicates. Of 55 sites enrolling patients, 40 are currently doing so...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth